Home | Screening data | Screen comparisons | Search for compounds | Structure search

Compound InformationSONAR Target prediction
Name:

FENOFIBRATE

Unique Identifier:SPE01501010
MolClass: Checkout models in ver1.5 and ver1.0
Molecular Formula:
Molecular Weight:339.664 g/mol
X log p:16.598  (online calculus)
Lipinksi Failures1
TPSA52.6
Hydrogen Bond Donor Count:0
Hydrogen Bond Acceptors Count:4
Rotatable Bond Count:7
Canonical Smiles:CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1
Source:synthetic
Therapeutics:antihyperlipidemic
Generic_name:Fenofibrate
Chemical_iupac_name:1-methylethyl2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoate
Drug_type:Approved Drug
Pharmgkb_id:PA449594
Kegg_compound_id:C07586
Drugbank_id:APRD00405
Melting_point:80.5 ᄚC
H2o_solubility:0.25mg/ml at 25 ᄚC
Logp:5.575
Cas_registry_number:49562-28-9
Drug_category:Antilipemic Agents; Fribic Acid Derivatives; ATC:C10AB05
Indication:For use as adjunctive therapy to diet to reduce elevated LDL-C,
Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with
primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)
Pharmacology:Fenofibrate is a lipid regulating agent indicated as adjunctive therapy to diet to
reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in
adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson
Types IIa and IIb). Fenofibrate is also indicated as adjunctive therapy to diet for
treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V
hyperlipidemia). Fenofibric acid, the active metabolite of Fenofibrate, produces
reductions in total cholesterol, LDL cholesterol, apolipoprotein B, total
triglycerides and triglyceride rich lipoprotein (VLDL) in treated patients. In
addition, treatment with fenofibrate results in increases in high density
lipoprotein (HDL) and apoproteins apoAI and apoAII.
Mechanism_of_action:Fenofibrate exerts its therapeutic effects through activation of peroxisome
proliferator activated receptor a (PPARa). This increases lipolysis and elimination
of triglyceride-rich particles from plasma by activating lipoprotein lipase and
reducing production of apoprotein C-III. The resulting fall in triglycerides
produces an alteration in the size and composition of LDL from small, dense
particles, to large buoyant particles. These larger particles have a greater
affinity for cholesterol receptors and are catabolized rapidly.
Organisms_affected:Humans and other mammals

Found: 10 active | as graph: single | with analogs << Back 1 2 3 4 5 6 7 8 9 10 Next >> 
Species: 4932
Condition: SPE00100009
Replicates: 2
Raw OD Value: r im 0.4370±0.0190212
Normalized OD Score: sc h 1.4617±0.0320727
Z-Score: 5.9219±1.78308
p-Value: 0.00000157316
Z-Factor: -8.99131
Fitness Defect: 13.3624
Bioactivity Statement: Active
Experimental Conditions
Library:SpectrumTMP
Plate Number and Position:2|C6
Drug Concentration:50.00 nM
OD Absorbance:595 nm
Robot Temperature:22.40 Celcius
Date:2006-11-15 YYYY-MM-DD
Plate CH Control (+):0.040525±0.00215
Plate DMSO Control (-):0.33294999999999997±0.14942
Plate Z-Factor:-0.0674
png
ps
pdf

DBLink | Rows returned: 2
3339 propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoate
3038934 ethyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoate

internal high similarity DBLink | Rows returned: 1
LOPAC 00410 1.0000

active | Cluster 14203 | Additional Members: 3 | Rows returned: 0

Service provided by the Mike Tyers Laboratory